Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | 2026-04-02 18:44:29 | 3.92 | -0.02 | -0.5 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGEN | 0001356090 | PRECIGEN, INC. | US74017N1054 | 549300XCWNQU35K64G19 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | VA | 20374 SENECA MEADOWS PARKWAY | GERMANTOWN | MD | 20876 | UNITED STATES | US | 301-556-9900 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | INTREXON CORP | Biotechnology | 1998-05-21 | — | 600 | http://precigen.com | 219,400,000 | 353,910,926 | 353,928,672 | Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. | 2026-04-02 17:12:32 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 219,400,000 | -20,400,000 | -8.5071 | 353,928,672 | 58,763,612 | 19.9087 |
| 2024 | 239,800,000 | 62,500,000 | 35.251 | 295,165,060 | 42,745,370 | 16.9342 |
| 2023 | 177,300,000 | 15,200,000 | 9.3769 | 252,419,690 | 224,977 | 0.0892 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Don Lehr | Chief Legal Officer | 2024 | 575,000 | 0 | 291,019 | 0 | 46,901 | 1,352,080 |
| Rutul Shah | Chief Operating Officer | 2024 | 452,116 | 0 | 305,249 | 0 | 46,334 | 1,407,544 |
| Helen Sabzevari | Chief Executive Officer | 2024 | 1,000,000 | 0 | 2,432,249 | 0 | 20,132 | 5,431,895 |
| Harry Thomasian Jr. | Chief Financial Officer | 2024 | 486,500 | 0 | 331,250 | 0 | 35,752 | 1,402,452 |
| Phil Tennant | Chief Commercial Officer | 2024 | 215,769 | 0 | 28,250 | 0 | 21,658 | 518,337 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 47 |
| 2024 | 99 |
| 2023 | 134 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 9,684,000 | 0 | 0 |
| Cost Of Revenue | 4,823,000 | 4,267,000 | 6,119,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 41,333,000 | 53,070,000 | 48,614,000 |
| General And Administrative Expenses | 70,128,000 | 41,293,000 | 40,415,000 |
| Operating Expenses | 120,191,000 | 138,954,000 | 105,983,000 |
| Operating Income | -110,507,000 | -135,029,000 | -99,758,000 |
| Net Income | -250,642,000 | -126,235,000 | -95,904,000 |
| Earnings Per Share Basic | -1.37 | -0.47 | -0.39 |
| Earnings Per Share Diluted | -1.37 | -0.47 | -0.39 |
| Weighted Average Shares Outstanding Basic | 312,980,562 | 267,727,426 | 244,536,221 |
| Weighted Average Shares Outstanding Diluted | 312,980,562 | 267,727,426 | 244,536,221 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 30,234,000 | 29,517,000 | 7,578,000 |
| Marketable Securities Current | 67,624,000 | 68,393,000 | 55,277,000 |
| Accounts Receivable | 3,916,000 | 926,000 | 902,000 |
| Inventories | 9,581,000 | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 115,235,000 | 102,414,000 | 68,755,000 |
| Marketable Securities Non Current | 2,511,000 | — | — |
| Property Plant And Equipment | 13,758,000 | 13,831,000 | 7,111,000 |
| Other Assets Non Current | 908,000 | 371,000 | 767,000 |
| Total Assets Non Current | 40,270,000 | 42,852,000 | 82,288,000 |
| Total Assets | 155,505,000 | 145,266,000 | 151,043,000 |
| Accounts Payable | 11,985,000 | 3,531,000 | 1,726,000 |
| Deferred Revenue | 517,000 | 589,000 | 509,000 |
| Short Term Debt | 0 | — | 0 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 37,306,000 | 21,518,000 | 22,985,000 |
| Long Term Debt | 93,174,000 | — | — |
| Other Liabilities Non Current | 134,000 | — | — |
| Total Liabilities Non Current | 97,288,000 | 57,017,000 | 9,560,000 |
| Total Liabilities | 134,594,000 | 78,535,000 | 32,545,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -2,341,348,000 | -2,090,706,000 | -1,964,471,000 |
| Accumulated Other Comprehensive Income | 7,000 | 12,000 | -1,947,000 |
| Total Shareholders Equity | 20,911,000 | 38,513,000 | 118,498,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 3,199,000 | 4,526,000 | 6,668,000 |
| Share Based Compensation Expense | 10,866,000 | 9,471,000 | 9,888,000 |
| Other Non Cash Income Expense | 0 | 0 | -2,000 |
| Change In Accounts Receivable | 2,990,000 | 24,000 | -76,000 |
| Change In Inventories | 9,209,000 | — | — |
| Change In Non Trade Receivables | 209,000 | -438,000 | -12,153,000 |
| Change In Other Assets | 556,000 | -120,000 | -129,000 |
| Change In Accounts Payable | 8,768,000 | 1,549,000 | -2,421,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -87,831,000 | -68,173,000 | -66,930,000 |
| Purchases Of Marketable Securities | 208,006,000 | 187,206,000 | 185,026,000 |
| Sales Of Marketable Securities | 208,466,000 | 175,016,000 | 183,377,000 |
| Acquisition Of Property Plant And Equipment | 1,995,000 | 8,584,000 | 1,536,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,535,000 | -20,714,000 | -3,087,000 |
| Tax Withholding For Share Based Compensation | 1,776,000 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | -355,000 | 31,237,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 92,818,000 | — | — |
| Repayment Of Long Term Debt | 0 | 0 | 43,219,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 90,048,000 | 110,583,000 | 29,589,000 |
| Change In Cash | 717,000 | 21,669,000 | -40,748,000 |
| Cash At End Of Period | 30,234,000 | 29,517,000 | 7,578,000 |
| Income Taxes Paid | 3,000 | 4,000 | 21,000 |
| Interest Paid | 3,510,000 | 7,000 | 1,171,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.37 | -0.47 | -0.39 |
| Price To Earnings Ratio | -3.0511 | -2.383 | -3.4359 |
| Earnings Growth Rate | 191.4894 | 20.5128 | -378.5714 |
| Price Earnings To Growth Ratio | -0.0159 | -0.1162 | 0.0091 |
| Book Value Per Share | 0.0668 | 0.2492 | 0.4846 |
| Price To Book Ratio | 62.5632 | 4.4935 | 2.7653 |
| Ebitda | -243,573,000 | -121,699,000 | -88,747,000 |
| Enterprise Value | 1,371,198,749.16 | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 4.4557 | — | — |
| Capital Expenditures | 3,126,000 | 11,246,000 | 6,450,000 |
| Free Cash Flow | -90,957,000 | -79,419,000 | -73,380,000 |
| Return On Equity | -11.9861 | -3.2777 | -0.8093 |
| One Year Beta | 1.7819 | 1.6578 | 2.1757 |
| Three Year Beta | 1.8376 | 1.8106 | 1.6677 |
| Five Year Beta | 1.6937 | 1.6063 | 1.6123 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| KIRK RANDAL J | Director, 10% owner | 2026-03-30 | 1,108,998 | D | 80,672,818 |
| KIRK RANDAL J | Director, 10% owner | 2026-03-30 | 50,797 | D | 426,695 |
| KIRK RANDAL J | Director, 10% owner | 2026-03-30 | 370,847 | D | 3,238,210 |
| KIRK RANDAL J | Director, 10% owner | 2026-03-30 | 152,063 | D | 1,463,571 |
| KIRK RANDAL J | Director, 10% owner | 2026-03-30 | 50,797 | D | 425,732 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| ADIRONDACK TRUST CO | 2026-03-31 | 3,870 | 1,000 | 3.87 |
| Ares Financial Consulting, LLC | 2026-03-31 | 24 | 6 | 4 |
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 9,087,040 | 2,173,933 | 4.18 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 3,712 | 888 | 4.1802 |
| Corient Private Wealth LLC | 2025-12-31 | 1,804,550 | 431,710 | 4.18 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Direxion Shares ETF Trust | 2026-01-31 | Direxion Daily S&P Biotech Bull 3X ETF | LABU | 248,246 | 1,114,624.54 | 0.1934 |
| Global X Funds | 2026-01-31 | Global X Russell 2000 ETF | RSSL | 81,509 | 365,975.41 | 0.0264 |
| Pacer Funds Trust | 2026-01-31 | Pacer WealthShield ETF | PWS | 4,866 | 21,848.34 | 0.0695 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND SERVICE CLASS | SLPSX | 189 | 848.61 | 0.0113 |
| ProFunds | 2026-01-31 | SMALL-CAP PROFUND INVESTOR CLASS | SLPIX | 189 | 848.61 | 0.0113 |